Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes

Drug Metabolism and Disposition

Volumn 37, Issue 12, 2009, Pages 2323-2329

  Moody, David E ^a   Fang, Wenfang B ^a   Lin, Shen Nan ^a   Weyant, Denise M ^b   Strom, Stephen C ^c   Omiecinski, Curtis J ^b  

^a UNIVERSITY OF UTAH   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; BUPRENORPHINE; BUPRENORPHINE 3 GLUCURONIDE; DIMETHYL SULFOXIDE; METHADONE; NELFINAVIR; NORBUPRENORPHINE; NORBUPRENORPHINE 3 GLUCURONIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG EFFECT; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER CELL CULTURE; LIVER MICROSOME; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ANALGESICS, OPIOID; ANTIBIOTICS, ANTITUBERCULAR; BIOTRANSFORMATION; BUPRENORPHINE; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; DEALKYLATION; DRUG INTERACTIONS; FEMALE; GLUCURONIDES; HEPATOCYTES; HIV PROTEASE INHIBITORS; HUMANS; INTESTINES; KINETICS; MALE; METHADONE; MICROSOMES, LIVER; MIDDLE AGED; NELFINAVIR; PYRROLIDINES; RIFAMPIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 71049166405     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028605     Document Type: Article

References (37)

1. Annaert PP and Brouwer KL (2005) Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 33:388-394.
2. Chang Y and Moody DE (2005) Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur J Clin Pharmacol 60:875-881. (Pubitemid 40386158)
3. Chang Y and Moody DE (2009) Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 3:101-107.
4. Chang Y, Moody DE, and McCance-Katz EF (2006) Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 34:440-448. (Pubitemid 43290902)
5. Cohn JA (2002) HIV-1 infection in injection drug users. Infect Dis Clin North Am 16:745-770.
6. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, and Johnson RE (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12:577-581.
7. Cowan A, Lewis JW, and Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545. (Pubitemid 8149539)
8. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, and Eap CB (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668-681. (Pubitemid 44920225)
9. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, and Eap CB (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593-604. (Pubitemid 41773635)
10. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
11. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, and Unadkat JD (2007) Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 35:1853-1859. (Pubitemid 47481578)
12. Eap CB, Buclin T, and Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153-1193. (Pubitemid 35398691)
13. Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, and Brouwer KL (2004) P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 21:1294-1302.
14. Huang W, Moody DE, and McCance-Katz EF (2006) The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit 28:245-251. (Pubitemid 44314956)
15. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, Beaune P, and Ménez JF (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 9:365-373. (Pubitemid 26079977)
16. Iribarne C, Picart D, Dréano Y, Bail JP, and Berthou F (1997) Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 60:1953-1964. (Pubitemid 27224184)
17. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, and Bigelow GE (2000) A comparison of levomethadol acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290-1297.
18. Kern A, Bader A, Pichlmayr R, and Sewing KF (1997) Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 54:761-772. (Pubitemid 27404677)
19. Kharasch ED, Hoffer C, Whittington D, and Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250-269. (Pubitemid 39221799)
20. Kharasch ED, Hoffer C, Whittington D, Walker A, and Bedynek PS (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology 110:660-672.
21. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UGP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
22. Kreek MJ, Garfield JW, Gutjahr CL, and Giusti LM (1976) Rifampin-induced methadone withdrawal. N Engl J Med 294:1104-1106.
23. McCance-Katz EF (2005) Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 41 (Suppl 1):S89-S95.
24. McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, et al. (2006a) Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 43 (Suppl 4):S224-S234. (Pubitemid 44901890)
25. McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, and Rainey PM (2007) Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 91:269-278.
26. McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, and Rainey PM (2006b) Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 43 (Suppl 4):S235-S246. (Pubitemid 44901891)
27. McCance-Katz EF, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, and Jatlow P (2004) Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict 13:163-180. (Pubitemid 38585697)
28. Mohutsky MA, Chien JY, Ring BJ, and Wrighton SA (2006) Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm Res 23:654-662.
29. Moody DE, Alburges ME, Parker RJ, Collins JM, and Strong JM (1997) The involvement of cytochrome P450 3A in the N-demethylation of L-α- acetylmethadol (LAAM), norLAAM and methadone. Drug Metab Dispos 25:1347-1353. (Pubitemid 28010919)
30. Moody DE, Chang Y, Huang W, and McCance-Katz EF (2009) The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol 105:211-215.
31. Moody DE, Lin SN, Chang Y, Lamm L, Greenwald MK, and Ahmed MS (2008) An enantiomer-selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine, and liver microsomes. J Anal Toxicol 32:208-219.
32. Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, and Foltz RL (2002) A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 306:31-39.
33. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, and Omiecinski CJ (2007) Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol 222:42-56. (Pubitemid 46964871)
34. Page JL, Johnson MC, Olsavsky KM, Strom SC, Zarbl H, and Omiecinski CJ (2007) Gene expression profiling of extracellular matrix as an effector of human hepatocyte phenotype in primary cell culture. Toxicol Sci 97:384-397. (Pubitemid 47073854)
35. Picard N, Cresteil T, Djebli N, and Marquet P (2005) In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 33:689-695. (Pubitemid 40593885)
36. Sidhu JS, Liu F, and Omiecinski CJ (2004) Phenobarbital responsiveness as a uniquely sensitive indicator of hepatocyte differentiation status: requirement of dexamethasone and extracellular matrix in establishing the functional integrity of cultured primary rat hepatocytes. Exp Cell Res 292:252-264. (Pubitemid 38018841)
37. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, and Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363-374. (Pubitemid 351304229)